Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

This trial is comparing two diabetes medications — tirzepatide (a newer dual hormone drug) and insulin glargine (a long-acting insulin) — to see how they affect blood sugar, fat metabolism, and brain function in people with type 2 diabetes that is not well-controlled on current oral medications. **You may be eligible if...** - You have type 2 diabetes - Your blood sugar (HbA1c) is between 7.5% and 11.0% - You have been on stable metformin (with or without sulfonylureas) for at least 2 months - You have not used insulin before (except briefly during pregnancy or illness) - Your BMI is 23 or higher **You may NOT be eligible if...** - You have type 1 diabetes - You are currently using insulin as a regular treatment - You have significant heart, kidney, or liver disease - You are pregnant or planning to become pregnant - You have a history of pancreatitis or certain thyroid cancers Talk to your doctor to see if this trial is right for you.